NetworkNewsBreaks – Alzamend Neuro, Inc. (NASDAQ: ALZN) Doses First Patient in Phase II Trial for Next-Gen Lithium Therapy AL001
Alzamend Neuro (NASDAQ: ALZN) announced the first patient has been dosed in its Phase II clinical trial of AL001, a novel lithium-based therapeutic designed to treat Alzheimer’s, bipolar disorder, major depressive disorder and PTSD. Conducted at Massachusetts General Hospital, the study in healthy subjects will evaluate AL001’s ability to deliver lithium more efficiently to the brain while minimizing systemic side effects, potentially eliminating the need for therapeutic drug monitoring. Backed by promising preclinical data showing improved brain absorption and reduced blood lithium levels, AL001 could mark a breakthrough in neuropsychiatric care. The therapy aims to address long-standing safety challenges associated with…
